


ISEC Healthcare Ltd.

("ISEC Healthcare" or the "Company")

BUILDING ON RECOVERY AND OPPORTUNITIES

9th Annual General Meeting
20th April 2023



This presentation has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This presentation has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this presentation.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Disclaimer

This presentation contains certain financial information and results of operation, and may also contain certain projections, plans, strategies and objectives of the Company which are not statements of historical fact but may constitute “forward-looking statements” that reflect the Company’s current views with respect to future events and financial performance. These views expressed herein are based on a number of estimates and current assumptions which are subject to business, economic and political uncertainties and contingencies, as well as various risks which are in many cases outside the control of the Company, and which may change over time and may cause the Company’s future results to be materially different than expected or indicated by such statements. No assurance can be given that future events will occur, that projections will be achieved, or that the Company’s assumptions are correct. Such forward-looking statements are not guarantees of future performance and accordingly, the actual results, financial conditions, performance or achievements of the Company may differ materially from those anticipated by the Company in the forward-looking statements. The information contained herein is current only as of its date and shall not, under any circumstances, create any implication that such information is correct as at any time subsequent to the date hereof or as there has been no change in the financial condition or affairs of the Company since such date. Opinions expressed herein reflect the judgment of the Company as of the date of this presentation and may be subject to change. This presentation may be updated from time to time and there is no undertaking by the Company to post any such amendments or supplements to this presentation. The Company will not be responsible for any consequences resulting from the use of this presentation, nor any undue reliance placed upon any opinion or statement contained herein.


Table of Content

Business Overview

Financial Highlights

Corporate Developments

Outlook



Business Overview

Business Overview
Our Presence



Number of Eye Care Centres
(as at 20th April 2023):


Malaysia – 8
Singapore – 1 (N1)
Myanmar – 1

N1 – Asia Pacific Eye Centre in Gleneagles Hospital.




Business Overview
Our Competitive Strengths

1. *Highly qualified and experienced specialist doctors*
2. *High quality and comprehensive range of eye care services*
3. *Well positioned to capture growing demand for private eye care services*
4. *Strong cash flow business model*
5. *Ability to replicate our business model which features state-of-the-art technology across markets*
6. *Business model aligns the interests of our specialist doctors with our Group and Shareholders*



Financial Highlights

Financial Highlights
Revenue – 5 Years (2018 – 2022)





The Group's revenue increased by 56%, from S$40.5 million in FY2021 to S$63.0 million in FY2022.

Generally, the Group showed an upward trend on revenue growth between FY2018 and FY2022, except in FY2020, revenue decreased by 15% when businesses were adversely affected by COVID-19.

Financial Highlights
Revenue Breakdown – By Business Segment

Revenue (S$'Million) and Contribution Percentage by Business Segment





FY2022 vs FY2021: Increased patient visits and business activities of the Group's operations in FY2022 in tandem with the resumption of business activities upon the lifting of respective international travel restrictions and relaxation of COVID-19 movement measures in FY2022.


Specialised Health Services: Revenue increased by S$21.7 million, or 59% compared to that in FY2021. Excluding the S$6 million contribution from IE Centre and Kampar Eye, which was acquired in May 2022, the Group's revenue showed an increase of S$15.8 million, or 43%, due to reasons stated above.

General Health Services: Revenue increased by S$0.8 million, or 20% compared to that in FY2021, with increased business activities during the year.

Financial Highlights

Revenue Breakdown – By Geographical Segment

Revenue (S$'Million) and Contribution Percentage by Geographical Segment




Malaysia: Revenue increased by S$19.2 million, or 63% compared to that in FY2021. Excluding S$6 million contribution from IE Centre and Kampar Eye, which was acquired in May 2022, the Group's revenue for FY2022 showed an increase of S$13.2 million, or 43%. Business activities improved significantly in FY2022 with increased patient visits following the lifting of respective international travel restrictions and relaxation of COVID-19 movement measures.

Singapore: Revenue increased by S$2.4 million, or 27% compared to that in FY2021. Patient visits increased in FY2022 with the lifting of respective international travel restrictions and relaxation of COVID-19 movement measures.

Myanmar: Revenue increased by S$0.9 million compared to that in FY2021 from increased patient visits.

Financial Highlights


Profit attributable to owners of Company – 5 Years (2018 – 2022)



The improved business activities in FY2022 translated to increased profits by S$5.6 million, or 81%, from S$6.9 million in FY2021 to S$12.5 million in FY2022.

In FY2020, the Group recognised impairment loss for goodwill arising from operations in general health services segment, amounting to S$1.5 million.

Financial Highlights
Earnings Per Share – 5 Years (2018 – 2022)




Earnings per share increased from 1.25 Singapore cents in FY2021 to 2.22 Singapore cents in FY2022.


Financial Highlights

Net Asset Value attributable to owners of Company – 5 Years (2018 – 2022)

Net Asset Value attributable to owners of Company (S$'Million)




Net Asset Value Per Share (S$)




Financial Highlights
Dividends

N1	Dividend Paid/Proposed (S$'Million)
Q2 2022 (Interim Dividend)	2.7
Q4 2022 (Final Dividend)	6.2
Total	**8.9**



N1 – Includes final dividend of 1.08 Singapore Cents proposed but not yet approved by the shareholders; to be tabled for approval in the AGM on 20 April 2023.



Corporate Developments

Corporate Developments
2022 – Significant Milestones





6 April 2022

Share Purchase and Subscription Agreement entered, for:

1) 100% acquisition of IE Centre and Kampar Eye; and
2) Subscription of 50% + 1 ordinary share in each of ME Centre, TE Centre and Taiping Eye


("Ipoh Eye Group of Clinics")

26 May 2022

Completion of Transaction – Ipoh Eye Group of Clinics

Continue to next slide

Corporate Developments
2022 – Significant Milestones





16 December 2022

ISEC Penang obtained operating licence to operate a specialist eye clinic and to provide ambulatory care service, and shifted operations to new enlarged premises

1) **27 January 2023** – Entry into Lease Agreement by ISEC Myanmar Co., Limited

- ISEC Myanmar had entered into a 2-year lease agreement with ARYU International Healthcare Company Limited, with a total gross floor area of 1,755 square feet.

- ISEC Myanmar plans to set up and operate an ophthalmology clinic at the premises ("**Myanmar Clinic**") for expansion of the Group's presence in Myanmar. The Myanmar Clinic will be named "ARYU International Specialist Eye Centre" and it is expected to commence full operations in February 2023.

2) **15 March 2023** – Business Update – ISEC (Kuching) Sdn. Bhd.

- ISEC Kuching has obtained the operating licence from the Ministry of Health Malaysia to operate an eye specialist clinic and to provide ambulatory care service at its new premises in Kuching, Sarawak, Malaysia.
- As such, the clinic commenced operations with effect from 20 March 2023.

Clinics Set-Up in Progress


Perak

- The three centres from the Ipoh Eye Transaction (ME Centre, TE Centre, Taiping Eye) are in the process of renovation. After the renovation, the Group will proceed to apply licences to operate or provide private healthcare facilities or services, and are expected to commence operations by early 2024.

Melaka

- We are in the process of expanding our centre, which we expect to be ready in the second half year of 2023. When completed, the Melaka centre will be about 50% larger than the current one.

With the above expansion plans in place in Malaysia, we hope to better reach out and serve both the local and foreign patients.



Outlook

Outlook


- We remain positive about the outlook for our Group as we are well-positioned to capture the growing demand for private eye care services.

- As the region ages and current lifestyle patterns continue to be highly influenced by digitalisation, we believe that there will be greater awareness and need for ophthalmology services.

- The rising affluence in our markets will also lead to more patients seeking out private eye care services.

Political Situation in Myanmar

- As the protests are still ongoing and the situation is still evolving, the Group remains cautiously optimistic and is closely monitoring our clinic operations in Myanmar.



Thank You